European Medicines Agency and ENCePP Launch 'ENCePP studies'
The
Investigators who apply to conduct an ENCePP study commit to a maximum level of transparency with respect to relevant information regarding their investigation. This includes publication of study findings regardless of their positive or negative results and making public relevant information on the study protocol before the study commences.
The seal ‘ENCePP studies’ is a confirmation for the public that the study was conducted in adherence to the ENCePP research and methodological principles and will increase trust in the robustness of the findings.
‘ENCePP studies’ is an important milestone for ENCePP, the European network of excellence in the fields of pharmacoepidemiology and pharmacovigilance. It builds on some of the network’s main achievements since 2007, specifically the adoption of an ENCePP Code of Conduct and the development of a checklist of methodological standards for ENCePP study protocols.
The ENCePP Code of Conduct is a set of rules and principles to ensure transparency and promote scientific independence. The Code is voluntary and lays down rights and obligations between investigators and study funders detailing their responsibilities in the conduct of studies. It covers aspects such as the development of the study protocol, the conduct of the study, data ownership, and access to data and publication of the results. In order to facilitate compliance with the transparency requirement outlined in the Code, the Agency is developing an electronic-register of studies, which will provide a publicly accessible resource for the registration and consultation of pharmacoepidemiological and pharmacovigilance studies.
The checklist of methodological standards for ENCePP study protocols is aimed at stimulating researchers to address important epidemiological principles when designing a pharmacoepidemiological study and writing a study protocol. Adherence to these principles will promote transparency regarding methodologies used in pharmacoepidemiological studies performed in the EU. It will also increase awareness of new developments in science and methodology in the field of pharmacoepidemiology.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025